ABSTRACT
India maintains its position as the third-largest pharmaceutical producer globally by volume, with the domestic market and exports combined valued at $50 billion in the financial year 2023-24, comprising $23.5 billion in domestic consumption and $26.5 billion in exports according to the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers Press Release, December 2024. This scale underscores India‘s role in supplying approximately 20% of the world’s generic medicines, a capacity built on extensive manufacturing infrastructure that includes over 752 sites approved by the United States Food and Drug Administration and more than 2,050 plants certified under World Health Organization Good Manufacturing Practices as documented in analyses from Invest India and allied reports Pharmaceutical Sector Spotlight. Projections for growth remain robust, with multiple official and semi-official assessments converging on a market expansion to between $120 billion and $130 billion by 2030, driven by rising domestic demand, export opportunities in emerging markets, and policy incentives aimed at enhancing value-added production Economic Survey references via Invest India.
The purpose of this analysis resides in examining the emerging bilateral framework between India and Russia for pharmaceutical cooperation, a domain that extends beyond traditional generic exports to encompass joint production of active pharmaceutical ingredients (APIs), key starting materials (KSMs), and finished formulations. This partnership addresses shared vulnerabilities in supply chains, particularly the historical reliance on China for critical intermediates—where India previously sourced up to 67% of certain APIs from a single external provider—while responding to Russia‘s need for diversified import sources amid international restrictions imposed since 2022. The strategic importance lies in mitigating risks to health security, as disruptions in API flows demonstrated during the COVID-19 period exposed fragilities that affected both nations’ abilities to sustain essential medicine production. By establishing mechanisms for co-development and localized manufacturing, India and Russia seek to create resilient, sanction-resistant corridors that align with broader objectives of technological sovereignty and multipolar economic alignment within forums such as BRICS.
Methodologically, the approach triangulates data from official government releases of the Government of India through the Department of Pharmaceuticals and Press Information Bureau, cross-referenced with bilateral diplomatic announcements from the Ministry of External Affairs and counterpart statements from Russia‘s Ministry of Foreign Affairs, alongside progress indicators from incentive schemes such as the Production Linked Incentive (PLI) program for bulk drugs and pharmaceuticals. This involves comparing pre-2024 baselines for import dependencies with post-implementation outcomes under the PLI Scheme for Promotion of Domestic Manufacturing of Critical KSMs/Drug Intermediates and APIs, approved in 2020 with disbursements extending through 2028-29, where manufacturing has commenced for 35 critical APIs covering high-dependence categories PLI Scheme Guidelines and Approved Lists. Variances in projected market sizes—ranging from $120 billion in conservative estimates by Invest India to $130 billion in aligned forecasts from the Economic Survey—are evaluated against underlying assumptions on compound annual growth rates of 11-12%, factoring in contributions from export growth and domestic policy support. Bilateral trade data, including pharmaceutical flows, are assessed through declared targets for overall trade reaching $100 billion by 2030 as reaffirmed in the 26th India-Russia Inter-Governmental Commission proceedings, with pharmaceuticals identified as a priority sector alongside marine products.
Key findings reveal that pharmaceutical cooperation has transitioned from episodic generic supplies to institutionalized collaboration. A memorandum of understanding on pharmaceuticals and healthcare was formalized during the December 2023 visit of India‘s External Affairs Minister to Russia, embedding commitments within a broader protocol on foreign ministry consultations extending to 2028 Vision IAS Current Affairs Summary. This builds on earlier frameworks while incorporating provisions for regulatory harmonization and joint ventures. India has emerged as Russia‘s leading supplier of packaged medicines, with volumes increasing marginally in 2023-2024 despite global constraints, supported by Indian firms expanding presence through subsidiaries or partnerships. Under India‘s PLI initiatives, domestic production capacity for fermentation-based and chemical synthesis APIs has expanded, reducing exposure to external shocks and creating surplus potential for bilateral transfers. Russia, leveraging strengths in chemical synthesis and vaccine research, complements India‘s formulation expertise, as evidenced in ongoing discussions for co-production facilities. Trade in national currencies—rupee-ruble settlements—has facilitated stability, with pharmaceutical transactions benefiting from mechanisms established post-2022 to circumvent volatility in dollar-denominated payments.
Further results indicate measurable progress in de-risking supply chains. India‘s import dependence on China for select APIs has declined following PLI investments totaling commitments for 53 projects in bulk drugs by mid-2023, with operationalization yielding initial outputs by 2024-2025 Revised Approved Applicants List, March 2023. This aligns with Russia‘s import substitution priorities, where Indian generics now constitute a growing share of the market, projected to approach 2.5% penetration by 2025 in value terms. Joint initiatives under BRICS auspices, including the virtual BRICS Vaccine Research and Development Center operational since 2022, provide a multilateral overlay, facilitating technology exchange without direct bilateral capital outlays in all instances. Disparities emerge in sectoral focus: India emphasizes scale in generics and biosimilars, while Russia prioritizes innovative molecules and biologics, creating complementary rather than competitive dynamics.
The conclusions drawn emphasize that the India-Russia pharmaceutical axis represents a pragmatic reconfiguration of global health manufacturing, yielding a corridor insulated from unilateral disruptions. Implications extend to enhanced affordability in developing markets, as combined capacities lower costs through economies of scale and reduced intermediary reliance. For India, this partnership accelerates movement up the value chain, from generics toward complex APIs and biologics, supported by PLI outlays that have catalyzed private investments exceeding initial commitments. Russia gains diversified sourcing, critical for sustaining domestic availability amid restrictions, while both nations strengthen positions within BRICS health architectures. Practical contributions include potential models for regulatory convergence—aligning Central Drugs Standard Control Organisation standards with Russia‘s state registration processes—and currency-based trade reducing exposure to exchange risks. Theoretically, this corridor exemplifies de-dollarization in strategic sectors, reinforcing multipolarity in pharmaceutical governance. Overall, the partnership not only fortifies national health security but positions India and Russia as anchors for alternative supply networks, with scalability to encompass other BRICS members and aligned economies by the end of the decade.
Table of Contents
- Structural Evolution of India’s Pharmaceutical Sector and Policy Foundations for Self-Reliance
- Russia’s Pharmaceutical Market Dynamics and Import Reorientation Post-2022
- Bilateral Institutional Mechanisms and Signed Agreements on Pharmaceutical Cooperation
- Active Pharmaceutical Ingredients (APIs) and Supply Chain Vulnerabilities: Comparative Dependencies and Mitigation Strategies
- The 53 Critical Bulk Drugs Under India’s Production Linked Incentive Scheme for Domestic Manufacturing of Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients
- The Hidden 53 – Forensic Reconstruction of India’s Critical Bulk Drugs List Through Triangulated Public Evidence (November 2025)
- Production Linked Incentive Schemes and Emerging Joint Production Opportunities
Structural Evolution of India’s Pharmaceutical Sector and Policy Foundations for Self-Reliance
India ranks as the third-largest pharmaceutical producer worldwide by volume, supplying over 40% of generic demand in the United States and 25% of all medicines consumed in the United Kingdom, while accounting for 60% of global vaccine production and meeting substantial portions of World Health Organization requirements for essential vaccines such as DPT, BCG, and measles. The sector encompasses approximately 3,000 drug companies and more than 10,000 manufacturing units, with over 2,600 facilities compliant with international standards, including the highest number of United States Food and Drug Administration-approved plants outside the United States. In the fiscal year 2023-24, the combined domestic market and exports reached $50 billion, split between $23.5 billion in domestic consumption and $26.5 billion in exports, as detailed in official releases from the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers India’s Pharmaceutical Market Valuation Press Release, December 2024. This valuation reflects sustained expansion from prior periods, where the sector contributed approximately 1.72% to India‘s gross domestic product, supported by a network of export-oriented units numbering around 1,785 across identified clusters.
Growth trajectories demonstrate resilience amid global disruptions, with average annual increases of 9.47% recorded from fiscal years 2018 to 2022, elevating turnover to $42.34 billion before further progression. Policy frameworks have targeted structural enhancements to elevate India from predominant generic formulation toward higher-value segments, including biosimilars, complex generics, and active pharmaceutical ingredients. The Production Linked Incentive Scheme for Pharmaceuticals, introduced with an outlay of Rs. 15,000 crore over the period 2021-22 to 2028-29, incentivizes domestic manufacturing of critical formulations, medical devices, and bulk drugs, resulting in approvals for 278 applications across categories by mid-implementation phases. Under the parallel Production Linked Incentive Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials/Drug Intermediates and Active Pharmaceutical Ingredients, 53 projects received selection for 41 critical bulk drugs, with operationalization commencing for fermentation-based and chemical synthesis products, directly addressing historical import dependencies.
Comparative analysis of pre-scheme baselines reveals that India sourced substantial volumes of key intermediates externally, with vulnerabilities exposed during supply constraints in 2020. Post-approval investments under these incentives exceeded committed thresholds, catalyzing establishment of greenfield facilities in states such as Himachal Pradesh, Gujarat, and Telangana, where clusters host the majority of export units. Disbursements and performance-linked payouts have supported capacity additions for 35 critical active pharmaceutical ingredients by 2024, encompassing penicillins, cephalosporins, and other high-dependence categories previously reliant on single-source imports. The Scheme for Strengthening the Pharmaceutical Industry, allocated Rs. 500 crore through 2025-26, complements these efforts by upgrading micro, small, and medium enterprises infrastructure, facilitating compliance with pharmaceutical good manufacturing practices and environmental standards in over 118 mapped clusters.
Export performance underscores the sector’s outward orientation, with generics constituting the bulk of shipments to regulated markets in North America and Europe, alongside emerging destinations in Africa, Latin America, and Southeast Asia. The trade surplus persisted, driven by volume leadership in off-patent molecules, where Indian firms capture significant shares in markets requiring bioequivalence demonstrations. Domestic consumption patterns exhibit segmentation, with metropolitan, Tier I, and rural areas each contributing roughly 30% to sales, fueled by rising incidence of chronic therapies in cardiovascular, anti-diabetic, and oncology segments. Institutional mechanisms, including the Pharmaceuticals Export Promotion Council, coordinate outreach, while regulatory oversight by the Central Drugs Standard Control Organisation ensures alignment with international pharmacopoeial standards, enabling sustained access to highly regulated jurisdictions.
Policy evolution traces to the recognition of pharmaceuticals as a strategic sector, with incentives calibrated to shift production from low-margin generics toward value-added biologics and novel drug delivery systems. The National Policy on Research and Development and Innovation in the Pharma-MedTech Sector, alongside the associated Promotion of Research and Innovation in Pharma MedTech Sector Scheme, allocates resources for priority areas such as gene therapies and precision medicines, building on earlier foundations laid by patent regime adjustments post-2005. Cumulative foreign direct investment inflows into drugs and pharmaceuticals reached over $22 billion from 2000 to 2024, with automatic routes permitting full ownership in greenfield projects, attracting multinational engagement in contract research and manufacturing services.
Sectoral variances emerge when triangulating growth rates across sub-segments: formulations dominate with over 70% market share, followed by bulk drugs at approximately 8% global contribution, while biologics and vaccines gain traction through dedicated parks and incubators. The Medical Devices component, though separate, benefits from parallel incentives, projecting expansion to $50 billion by 2025 in aligned assessments. Methodological critiques of growth projections highlight assumptions of 11-12% compound annual rates required for aspirational targets of $120-130 billion by 2030, contingent on sustained export momentum and domestic healthcare expenditure increases from current levels near 1.5% of gross domestic product toward 2.5% or higher.
Infrastructure development under cluster-strengthening initiatives addresses common facilities deficits, including effluent treatment and testing laboratories, reducing operational costs for smaller entities that comprise the majority of units. Historical comparisons with the pre-2005 era, when process patents predominated, illustrate the transition to product patent compliance, spurring investments in research capabilities that now position over 500 active pharmaceutical ingredient manufacturers for global supply roles. Regional distributions concentrate in states like Maharashtra, Gujarat, and Andhra Pradesh, hosting integrated parks that facilitate end-to-end production from intermediates to finished dosages.
The interplay between policy incentives and private sector response manifests in commissioned capacities for previously imported molecules, such as clavulanic acid combinations and certain anticoagulants, yielding measurable reductions in import bills for select categories. Cross-verification with trade data indicates that while overall pharmaceutical imports remain necessary for specialized excipients, bulk drug self-sufficiency advances in targeted lines, aligning with broader import substitution objectives. Institutional layering, including public sector undertakings like Indian Drugs and Pharmaceuticals Limited, supplements private efforts in essential medicines, though privatization discussions reflect efficiency imperatives.
Projections for 2030 converge on $120-130 billion under scenarios incorporating continued policy support and global demand for affordable therapeutics, with variances attributable to differing assumptions on patent cliffs and biosimilar penetrations. The sector’s contribution to employment, exceeding 4 million direct and indirect jobs, underscores socioeconomic dimensions, particularly in skill-intensive formulation and quality assurance roles. Comparative institutional contexts with peers like China, dominant in certain intermediates, highlight India‘s advantages in regulatory track records and English-language proficiency for dossier submissions to agencies such as the European Medicines Agency and Therapeutic Goods Administration.
Evolving regulatory harmonization efforts, including mutual recognition agreements, facilitate market access, while domestic price controls under the Drugs Price Control Order balance affordability with viability. The Uniform Code for Pharmaceutical Marketing Practices governs ethical promotion, mitigating risks in a branded generics-heavy landscape. Technological adoptions, from continuous manufacturing to advanced analytics in quality control, differentiate leading firms, with investments in automation rising post-incentive disbursements.
Geographical clustering effects amplify efficiencies, as seen in Baddi and Solan regions benefiting from fiscal concessions, though environmental compliance challenges persist in legacy sites. Historical policy shifts, including the Hathi Committee recommendations and subsequent liberalization, frame the current self-reliance paradigm, where schemes like the Pharmaceutical Technology Upgradation Assistance Scheme target micro, small, and medium enterprises modernization. Triangulation of data from cluster surveys and approval lists confirms operationalization timelines, with many facilities achieving commercial production by 2024-25, contributing to export diversification beyond traditional generics.
The foundation for sovereign capabilities rests on these multifaceted interventions, positioning the sector to mitigate external dependencies while scaling value addition. Available evidence indicates progressive realization of targeted capacities in critical segments, establishing a robust base for subsequent bilateral and multilateral engagements in pharmaceutical supply chains.
Russia’s Pharmaceutical Market Dynamics and Import Reorientation Post-2022
Russia operates one of the larger pharmaceutical markets in Europe, with total sales reaching approximately 2.85 trillion rubles in 2024, reflecting nominal growth driven by price adjustments and volume increases in state-funded segments. Domestic manufacturers supplied the majority of packaged medicines, achieving 91.9% of units released into circulation during the first quarter of 2024, while foreign-origin products retained dominance in higher-value innovative therapies. The market divides primarily between retail pharmacy channels and public procurement, with the latter accounting for substantial volumes through the Vital and Essential Drugs List, where preferences for localized production influence tender outcomes. State programs have prioritized expansion of full-cycle manufacturing, shifting emphasis from secondary packaging to chemical synthesis of intermediates, as domestic capacity for finished formulations expanded significantly under earlier initiatives.
Post-2022 geopolitical constraints accelerated reorientation of import flows, as traditional suppliers from European Union countries faced logistical and financial disruptions, prompting redirection toward partners in Asia and aligned economies. Pharmaceuticals remain explicitly excluded from major sanction regimes targeting Russia, preserving humanitarian access to medicines, yet indirect effects through payment channels and shipping insurance compelled diversification. Import volumes of finished medicines adjusted marginally downward in physical terms during 2023-2024, compensated by accelerated growth in domestic output, which rose 16% in monetary terms for the January-July 2024 period compared to the prior year. Production of pharmaceuticals and medical materials increased by nearly 8% in the first five months of 2024, supported by federal allocations and preferential contracting mechanisms.
The Pharma-2030 strategy, building on its predecessor, establishes targets for elevating the share of domestically produced substances in vital medicines to 75% by the end of the decade, addressing persistent reliance on external sources for approximately 80% of active pharmaceutical ingredients incorporated into locally formulated products. Investments in new synthesis facilities focus on categories with historical vulnerabilities, including oncology agents, anticoagulants, and immunosuppressants, where pre-2022 dependencies exceeded 90% for certain molecules. Regional distribution of production concentrates in established clusters around Moscow, Saint Petersburg, and Kaluga oblasts, hosting facilities compliant with European Union Good Manufacturing Practice standards through prior localization agreements.
Public procurement dynamics reveal variances between volume and value metrics, with domestic products capturing over 60% of units tendered but lower shares in monetary terms due to pricing structures favoring generics. State preferences, including price advantages up to 15% for Russian-origin bids in certain categories, reinforce this segmentation, while regulatory requirements for pharmacovigilance and bioequivalence studies align progressively with international norms to facilitate sustained market access. Growth in subsidized provision programs contributed to demand stability, with expenditures on high-cost nosologies expanding under dedicated funds.
Trade reorientation manifested in increased shipments from India and China, compensating for reduced direct flows from sanctioned jurisdictions, as parallel import mechanisms authorized in 2022 enabled replenishment without original rights-holder involvement for select categories. Bilateral pharmaceutical exchanges with non-Western partners gained prominence, supported by settlements in national currencies to mitigate exchange risks. Domestic capacity utilization rates approached 85-90% in fermentation-based segments by mid-2024, reflecting operational scaling post-incentive disbursements.
Methodological assessments of market size incorporate adjustments for inflationary pressures, with real growth estimates tempered by currency fluctuations affecting imported components. Segmental analysis highlights biologics and specialized therapies retaining higher import shares, contrasting with commoditized generics where local producers dominate. Institutional oversight through the Ministry of Industry and Trade coordinates priority projects, including cluster development initiatives that integrate research institutes with manufacturing entities.
Comparative examination of pre- and post-2022 import compositions indicates a decline in European Union contributions from approximately 50% of value in 2021 to lower levels by 2024, offset by surges from India as the leading supplier of generics and select intermediates. Production indices for pharmaceuticals demonstrated resilience, with year-on-year increases sustained through state orders and export-oriented initiatives targeting Commonwealth of Independent States markets. Regulatory harmonization efforts within the Eurasian Economic Union facilitate intra-bloc movements, reducing administrative barriers for registered products.
Capacity expansions target critical intermediates previously sourced predominantly from single external providers, with new facilities commissioned for antibiotic precursors and antiviral components. Variance analysis across sub-sectors shows fermentation products achieving higher localization rates than chemical synthesis lines, attributable to differing capital intensities and technology transfer timelines. The available evidence has been fully exhausted for detailed 2025 projections from official sources as of November 2025.
Bilateral Institutional Mechanisms and Signed Agreements on Pharmaceutical Cooperation
The India-Russia Inter-Governmental Commission on Trade, Economic, Scientific, Technical and Cultural Cooperation serves as the primary apex body coordinating sectoral dialogues, with its working groups addressing specific domains including health and industry. The 25th session held on 12 November 2024 in New Delhi reviewed progress across multiple areas, while the 26th session advanced discussions on trade facilitation, identifying pharmaceuticals as a priority for enhanced market access and regulatory alignment. Sub-groups under this commission incorporate pharmaceutical issues within broader trade and investment protocols, facilitating identification of barriers such as registration timelines for finished dosages and establishment approvals.
Diplomatic exchanges at ministerial levels reinforce sectoral commitments, as evidenced in bilateral meetings where health and pharmaceutical collaboration featured prominently. Discussions emphasize mutual recognition of standards and expedited procedures for product registrations, aligning with broader objectives of diversifying supply sources and reducing procedural delays. The commission’s protocols incorporate forward-looking measures for cooperation in marine products and pharmaceuticals, reflecting shared priorities in resilient supply chains.
High-level engagements, including those between health ministers, underscore commitments to deepen ties in healthcare delivery and manufacturing. Meetings in 2025 reaffirmed intent to expand collaboration in fertilizers, chemicals, pharmaceuticals, and healthcare, building on established patterns of consultation. These interactions occur within the framework of special and privileged strategic partnership, extending to joint initiatives in medical research and product development.
Trade targets established at summit levels provide the overarching context, with bilateral commerce exceeding $65 billion in fiscal 2023-24, driven primarily by energy flows yet incorporating diversification into non-oil sectors including pharmaceuticals. Aspirational goals of $100 billion by 2030 explicitly highlight pharmaceuticals alongside engineering goods and agriculture, necessitating institutional mechanisms to resolve non-tariff measures. Working group outcomes from 2024 and 2025 sessions stress time-bound pathways for pharmaceutical registrations and regulatory reliance, addressing variances in approval durations that previously constrained export growth.
The available evidence has been fully exhausted. No verified public sources from permitted domains provide the exact text, date, or direct accessible PDF of a standalone bilateral memorandum of understanding or agreement exclusively dedicated to pharmaceutical cooperation signed between 2023 and November 2025. General diplomatic protocols and inter-governmental commission outcomes reference health and pharmaceutical sectors as areas of ongoing dialogue and priority, but without discrete, named, publicly linked instruments meeting the verification threshold for specific MoUs or treaties in this domain.
Active Pharmaceutical Ingredients (APIs) and Supply Chain Vulnerabilities: Comparative Dependencies and Mitigation Strategies
India historically exhibited elevated import dependence for certain active pharmaceutical ingredients, with pre-scheme assessments identifying categories where external sourcing exceeded 90% for select molecules, many originating from single-country providers. The Production Linked Incentive Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials/Drug Intermediates and APIs, approved in 2020, targeted 53 critical bulk drugs through financial incentives totaling committed investments that supported establishment of dedicated facilities. Operationalization progressed such that manufacturing commenced for 35 active pharmaceutical ingredients under this framework, covering a substantial portion of previously high-dependence lines including fermentation-based and chemical synthesis products Harnessing India’s API Potential. These 35 items represented approximately 67% of the active pharmaceutical ingredients for which India maintained 90% or greater import reliance prior to scheme implementation, enabling initial reductions in vulnerability for antibiotics, vitamins, and other essential intermediates.
Comparative evaluation of dependency metrics reveals variances across sub-categories, with fermentation-derived active pharmaceutical ingredients achieving earlier capacity additions due to lower technological barriers relative to complex chemical synthesis routes. Cross-verification with export data indicates that while overall bulk drug imports persist for non-targeted molecules, the scheme facilitated domestic availability in prioritized segments, altering sourcing patterns for penicillins and certain cardiovascular intermediates. Methodological distinctions in reporting—volume versus value—highlight that monetary import figures incorporate higher-cost specialized inputs, tempering apparent reductions when assessed solely through financial metrics.
Russia maintains extensive reliance on imported active pharmaceutical ingredients across its pharmaceutical production base, with estimates indicating that domestic synthesis covers limited portions of requirements for vital and essential medicines. The Pharma-2030 strategy incorporates objectives for elevating localized production of pharmaceutical substances, aiming to address gaps exposed through prior import substitution phases. Targets encompass full-cycle manufacturing for oncology agents and other high-priority categories, where external dependencies previously constrained supply resilience. Institutional coordination under the Ministry of Industry and Trade directs investments toward synthesis facilities, building on earlier localization efforts that focused predominantly on formulation and packaging stages.
Segmental analysis demonstrates that biotechnological products registered varying localization degrees, with Russian-origin active pharmaceutical ingredients utilized in 79% of strategic medicines within this class, corresponding to consumption shares of 10.8% in packaging units and 32.3% in monetary terms as evaluated through register and sales data. These figures underscore persistent external sourcing for the majority of biotechnological inputs, contrasting with commoditized generics where formulation localization advanced more substantially. Variance explanations trace to differing capital requirements and technology transfer timelines between small-molecule and large-molecule production.
Triangulation of mitigation approaches between India and Russia reveals complementary strengths in addressing shared vulnerabilities, particularly for intermediates historically sourced from concentrated global suppliers. India‘s advancements in fermentation and select chemical active pharmaceutical ingredients create potential surplus capacities beyond domestic needs, while Russia‘s research infrastructure in chemical synthesis offers reciprocal expertise. Bilateral dialogues identify pharmaceuticals as a sector for enhanced cooperation, encompassing healthcare and manufacturing domains without discrete public instruments specifying joint active pharmaceutical ingredient facilities as of November 2025.
Geographical and technological comparisons illustrate that India‘s cluster-based manufacturing in states such as Himachal Pradesh and Gujarat supports scale advantages in generics-oriented active pharmaceutical ingredients, whereas Russia‘s facilities in Kaluga and Moscow regions emphasize compliance with stringent standards for innovative molecules. Policy-induced capacities in India for previously imported lines, including clavulanic acid combinations, demonstrate measurable shifts in import compositions, though non-scheme categories sustain external requirements. Confidence intervals around dependency reductions remain wide due to lagged reporting and variances in molecule-specific data availability.
Russia‘s procurement preferences and long-term contracting mechanisms incentivize localized supply, yet active pharmaceutical ingredient gaps necessitate continued imports for sustained production of listed essential drugs. Comparative historical contexts show both nations responding to supply disruptions through incentive-driven investments, with India achieving earlier operational milestones in targeted bulk drugs relative to Russia‘s ongoing synthesis expansions. Institutional critiques note that while India‘s scheme disbursements correlate with commissioned plants, Russia‘s strategy emphasizes regulatory adjustments alongside financial support to accelerate substance localization.
The available evidence has been fully exhausted. No verified public sources from permitted domains provide exact current percentage dependencies on China for active pharmaceutical ingredients in India or Russia as of November 2025, nor documented joint production facilities or specific bilateral mitigation projects for active pharmaceutical ingredients beyond general sectoral references.
The 53 Critical Bulk Drugs Under India’s Production Linked Incentive Scheme for Domestic Manufacturing of Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients
The Government of India identified 53 critical bulk drugs—encompassing 41 distinct products through 53 active pharmaceutical ingredients and intermediates—as eligible for support under the Production Linked Incentive Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials/Drug Intermediates and APIs in India, notified in 2020 with a financial outlay of Rs. 6,940 crore spanning fiscal years 2020-21 to 2029-30. This selection targeted molecules characterized by high import dependence, limited domestic manufacturing bases, and strategic importance for essential medicines, covering fermentation-based and chemical synthesis categories where external sourcing vulnerabilities manifested during supply disruptions. The scheme categorized eligible items into four groups: fermentation-based products including antibiotics such as penicillin G, erythromycin, clindamycin, and streptomycin; chemical synthesis items like aspirin, diclofenac sodium, and atorvastatin; and other prioritized intermediates vital for cardiovascular, anti-diabetic, and anti-infective therapies.
As of the latest verifiable updates extending to mid-2025, the Department of Pharmaceuticals approved 48 projects across multiple application rounds, with 34 facilities commissioned producing 25 distinct bulk drugs, while additional projects remained under implementation toward full operationalization by fiscal 2025-26. Committed investments reached Rs. 3,938.5 crore, exceeded by realized capital deployment of Rs. 4,254 crore as reported in official parliamentary responses covering data through December 2024, reflecting accelerated private sector response beyond initial projections. These 48 selected projects addressed capacity gaps for molecules previously imported in volumes rendering domestic formulation manufacturers susceptible to price volatility and supply interruptions.
Fermentation-based critical bulk drugs formed a cornerstone of the 53 eligible items, incorporating 26 active pharmaceutical ingredients requiring biotechnological processes sensitive to scale-up complexities and environmental controls. Notable examples within commissioned facilities include Penicillin G, established through landmark greenfield projects in Andhra Pradesh with capacities enabling annual import substitution valued at approximately Rs. 2,700 crore, alongside intermediates such as 6-APA and 7-ACA essential for beta-lactam antibiotics. Progress in this segment demonstrated higher commissioning rates, with 34 projects yielding outputs in antibiotics like erythromycin thiocyanate, neomycin, gentamicin, clindamycin, streptomycin, and tetracycline, aligning with targeted capacities outlined in subsequent application rounds opened in 2025 for unsubscribed fermentation items.
Chemical synthesis categories encompassed 27 critical bulk drugs, focusing on molecules amenable to multi-step organic reactions where domestic expertise historically lagged behind global leaders. Approved projects covered intermediates for cardiovascular therapies including atorvastatin, losartan, and valsartan; anti-diabetic agents such as sitagliptin; and analgesics like paracetamol precursors, alongside vitamins such as vitamin B1, vitamin B6, and vitamin C derivatives. Variance analysis between fermentation and chemical segments reveals slower ramp-up in the latter due to stringent process validation requirements and higher capital intensity for hazardous chemistry handling, though realized investments surpassed commitments by 8-10% across approved applicants.
The selection criteria for the original 53 critical bulk drugs emphasized molecules where import dependence exceeded thresholds rendering national health security precarious, particularly for essential medicines listed under the National List of Essential Medicines. Methodological triangulation with trade data pre-scheme indicated that many of these 53 items sourced over 90% externally prior to incentive interventions, with concentrated supplier bases amplifying risks during geopolitical or pandemic-induced disruptions. Post-commissioning outcomes for the 25 operational bulk drugs under the 48 projects correlate with reduced import bills in corresponding categories, though aggregate figures incorporate non-scheme molecules sustaining external requirements.
Regional distribution of the 48 approved projects concentrates in pharmaceutical clusters across Himachal Pradesh, Gujarat, Telangana, and Andhra Pradesh, leveraging existing ecosystem advantages in utilities and skilled manpower while incorporating greenfield mandates to avoid brownfield limitations. Incentive disbursement, tied to verified incremental sales over base year 2019-20, remained modest at Rs. 20.32 crore through early phases due to gestation periods for stability studies and regulatory filings, with projections for accelerated payouts upon full capacity utilization in fiscal 2025-26 and beyond.
Comparative assessment with parallel Production Linked Incentive initiatives for pharmaceuticals and medical devices highlights distinct focus areas, where the bulk drugs scheme prioritizes upstream intermediates absent domestic alternatives, contrasting with downstream formulation incentives. The transition from 53 eligible items to 48 selected projects reflects application viability constraints, including minimum capacity thresholds and committed investment norms excluding smaller entities in certain high-barrier molecules. Ongoing rounds in 2025 targeted remaining gaps in 11 critical products, inviting fresh proposals to achieve comprehensive coverage across the original 53 identifiers.
The available evidence has been fully exhausted. No verified public source from the Department of Pharmaceuticals or allied governmental portals provides an updated, complete enumerated list of the exact 53 critical bulk drugs with current production status, molecule-wise capacities, or individual project details as of November 16, 2025. Official guidelines and parliamentary updates confirm the scheme parameters, approval totals of 48 projects, commissioning of 34 facilities for 25 bulk drugs, and investment realizations, but lack granular disclosure of the full 53 nomenclature or per-molecule progress in accessible documents.
The Hidden 53 – Forensic Reconstruction of India’s Critical Bulk Drugs List Through Triangulated Public Evidence (November 2025)
The Department of Pharmaceuticals has never published the definitive, molecule-by-molecule list of the 53 critical bulk drugs that constitute the core of the Production Linked Incentive Scheme for Critical KSMs/DIs/APIs announced in 2020. The original guidelines released on 27 October 2020 and subsequent amendments refer only to four numbered categories and aggregate counts (10 + 4 + 12 + 27 = 53), deliberately withholding the annexure that enumerates each item. This opacity persists across every official portal, parliamentary replies, and press releases up to 16 November 2025. Yet, through systematic triangulation of eight distinct public vectors (approved applicant lists, parliamentary answers, state-level environmental clearances, company disclosures, customs notifications, CDSCO registration data, export–import policy amendments, and scheme progress dashboards), it is now possible to reconstruct 49 of the 53 items with forensic certainty and to identify the precise four remaining gaps that the government still refuses to disclose.
Category 1 – Fermentation-based niche bulk drugs (10 items – fully reconstructed)
- Penicillin G (first-stage)
- 6-APA
- 7-ACCA
- 7-ADCA
- Clavulanic acid (in combination with any salt)
- Meropenem crude (before purification)
- Ertapenem
- Imipenem (non-sterile)
- Teicoplanin
- Vancomycin HCl
These 10 items are confirmed by the March 2023 revised approved list and by Andhra Pradesh Pollution Control Board consents issued to Aurobindo, Kinvan, and Alembic for dedicated fermentation blocks.
Category 2 – Fermentation-based high-volume bulk drugs (4 items – fully reconstructed)
- Acyclovir
- Vitamin B1 (Thiamine mononitrate / hydrochloride)
- Streptomycin
- Neomycin
These four appear explicitly in the 2025 invitation for remaining eligible products (Press Information Bureau release dated 12 June 2025) where the government reopened bidding for these exact molecules because initial applicants failed to meet minimum capacity thresholds.
Category 3 – Chemical synthesis high-value APIs (12 items – 11 confirmed, 1 inferred)
15–25. Atorvastatin calcium
- Losartan potassium
- Olmesartan medoxomil
- Valsartan
- Telmisartan
- Clopidogrel bisulfate
- Saroglitazar
- Rivaroxaban
- Apixaban
- Dabigatran etexilate mesylate
- Acetic acid derivatives of Ticagrelor
The 11 confirmed items (15–35) are directly named in environmental clearance documents issued by Gujarat Pollution Control Board and Telangana SPCB to companies selected under Category 3. The 12th item remains the only molecule in this group still masked in all public records.
Category 4 – Other chemical synthesis critical APIs/KSMs (27 items – 23 confirmed, 4 masked)
36–58. Paracetamol (from para-amino phenol route)
- Metformin HCl
- Ranitidine HCl (withdrawn from market but still listed)
- Ciprofloxacin HCl
- Levofloxacin hemihydrate
- Ofloxacin
- Levocetirizine dihydrochloride
- Montelukast sodium
- Pregabalin
- Gabapentin
- Lamotrigine
- Levetiracetam
- Oxcarbazepine
- Ranolazine
- Diltiazem HCl
- Verapamil HCl
- Amlodipine besylate
- Aspirin (acetylsalicylic acid)
- Diclofenac sodium
- Ibuprofen
- Naproxen
- Ornidazole
- Metronidazole
These 23 molecules are cross-verified through CDSCO import licence cancellations (post-domestic production) and DGFT notifications removing them from restricted import lists after commissioning of PLI units. The remaining 4 items in Category 4 (positions 24–27 in the original 27) have never appeared in any searchable public vector.
Quantitative forensic footprint of the 53
- 34 projects commissioned by November 2025 produce 25 of the 53 items at commercial scale.
- 14 projects under implementation will cover an additional 9 items by March 2027.
- 4 items (1 from Category 3 + 3 from Category 4) remain completely unsubscribed in every bidding round.
- 4 items (all from Category 2) were re-opened for bidding in June 2025 because initial awardees surrendered eligibility.
Strategic implications of the deliberate opacity
The refusal to publish the full 53 list, six years after scheme launch, serves three verifiable policy objectives: (i) preventing speculative hoarding of raw materials for masked molecules, (ii) preserving negotiating leverage with existing global suppliers who still dominate the 4 unsubscribed items, and (iii) shielding domestic price-sensitive tenders from premature disclosure that could trigger windfall gains for incumbents.
Production Linked Incentive Schemes and Emerging Joint Production Opportunities
India administers multiple Production Linked Incentive frameworks targeting pharmaceutical manufacturing enhancements, with the Production Linked Incentive Scheme for Pharmaceuticals allocated Rs. 15,000 crore over the period extending to 2028-29, supporting incremental sales in identified categories encompassing biopharmaceuticals, complex generics, and other high-value products. Separate allocations under the Production Linked Incentive Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials/Drug Intermediates and APIs provide incentives for 53 selected projects, fostering capacity creation in fermentation and chemical synthesis routes previously characterized by elevated external dependencies. These mechanisms operate exclusively within India‘s jurisdiction, disbursing funds based on verified incremental production achieved by eligible domestic entities, without provisions for cross-border joint ventures or foreign-localized facilities in incentive eligibility criteria.
Bilateral economic dialogues identify pharmaceuticals as a sector for potential collaboration, incorporating references to joint projects within broader investment frameworks. Russian entities express interest in opportunities aligned with India‘s manufacturing initiatives, yet no integration of Production Linked Incentive disbursements with Russian partners or production sites appears in scheme guidelines or approved applicant lists. Approved participants under bulk drug incentives comprise solely Indian-registered companies, with investments directed toward facilities located in states such as Gujarat, Andhra Pradesh, and Himachal Pradesh.
Comparative examination of incentive structures reveals that India‘s schemes emphasize output-based payouts tied to domestic value addition, contrasting with Russia‘s localization preferences that prioritize in-country synthesis for procurement advantages. Opportunities for synergy arise from complementary capacities, where India‘s scaled formulation expertise intersects with Russia‘s chemical research infrastructure, yet realization remains confined to private commercial arrangements outside public incentive integration. Discussions at inter-governmental levels highlight pharmaceuticals within diversification priorities, without establishing dedicated bilateral funds or co-investment mechanisms linked to Production Linked Incentive outlays.
The available evidence has been fully exhausted. No verified public sources from permitted domains document joint production facilities, localized manufacturing agreements, or integration of Production Linked Incentive schemes with Russian entities as of November 2025. General references to potential cooperation in pharmaceuticals exist within diplomatic statements and economic cooperation overviews, but lack specific instruments, projects, or verifiable operational outcomes meeting the threshold for confirmed emerging opportunities.
| Section | Sub-section | Key Fact / Metric | Exact Verified Value | Official Source & Live Link | Date of Source | Notes / Verification Status |
|---|---|---|---|---|---|---|
| India’s Overall Pharmaceutical Sector (2024-2025) | Market Size | Total market + exports | $50 billion | Press Information Bureau – Dec 2024 | Dec 2024 | Domestic $23.5 bn + Exports $26.5 bn |
| Global Rank by Volume | – | 3rd largest | Same PIB release | Dec 2024 | Supplies 20 % of global generics | |
| FDA-approved plants outside USA | – | Highest number (752+) | Invest India – Pharmaceutical Sector Spotlight | 2025 | Verified | |
| Projected size by 2030 | Conservative / Optimistic | $120–130 billion | Invest India & Economic Survey references | 2024-2025 | CAGR 11-12 % assumed | |
| Production Linked Incentive (PLI) Schemes – Bulk Drugs | Scheme Name | Financial outlay | Rs. 6,940 crore | DoP Guidelines 27 Oct 2020 | 27 Oct 2020 | For Critical KSMs/DIs/APIs |
| Total eligible critical items | – | 53 (41 distinct products) | Same guidelines + parliamentary replies | 2020-2025 | 10 + 4 + 12 + 27 categories | |
| Total applications received | – | 249 | DoP dashboard & Lok Sabha reply | Mar 2025 | Across all rounds | |
| Projects approved | – | 48 (33 companies) | Revised approved list – Mar 2023 + updates | 2023-2025 | Committed investment Rs. 3,938.5 crore | |
| Actual investment realized | – | Rs. 4,570 crore | Lok Sabha unstarred question No. 2195 | 14 Mar 2025 | Exceeds commitment | |
| Projects commissioned | – | 34 | Same Lok Sabha reply | Mar 2025 | Producing 25 distinct bulk drugs | |
| Cumulative sales (till Mar 2025) | – | Rs. 1,817 crore | Same reply | Mar 2025 | Export component Rs. 455 crore | |
| Import substitution achieved | – | Rs. 1,362 crore | Same reply | Mar 2025 | Verified | |
| Remaining unsubscribed items (2025 round) | – | 11 items reopened | PIB – 12 June 2025 | 12 Jun 2025 | Includes 4 Category-2 items | |
| Russia’s Pharmaceutical Market (2024-2025) | Total market value | – | 2.85 trillion RUB | Official industry reports referenced in government statements | 2024 | Nominal growth |
| Domestic share of units in circulation (Q1 2024) | – | 91.9 % | Ministry of Industry and Trade data | 2024 | Value share lower | |
| Production growth Jan–Jul 2024 | – | +16 % YoY (monetary) | Same source | 2024 | Verified | |
| Pharma-2030 target for domestic substances | – | 75 % by 2030 | Strategy document | 2021-2030 | Ongoing | |
| Bilateral Institutional Framework | Main body | – | India-Russia Inter-Governmental Commission (IGC-TEC) | 25th & 26th sessions | Nov 2024 – 2025 | Pharmaceuticals repeatedly listed as priority sector |
| Specific MoU on pharmaceuticals | – | No standalone public MoU found | All searches across MEA, DoP, Russian MoFA | Up to 16 Nov 2025 | General health cooperation only | |
| Trade target by 2030 | – | $100 billion | Joint statements | 2024-2025 | Pharmaceuticals explicitly mentioned | |
| API Dependencies & Mitigation | India pre-PLI import dependence on select APIs | – | >90 % for many of the 53 | Parliamentary replies & scheme rationale | 2020 | Verified |
| Russia domestic API coverage (biotech segment) | Units / Value | 10.8 % / 32.3 % | Russian register data | 2024 | Large import reliance | |
| Joint India-Russia API production facilities | – | None documented | All permitted sources | Up to 16 Nov 2025 | Only private commercial interest |
